<div>At just 8 years old, Harper has already shown the world what courage looks like.
</div>
<div><br />
</div>
<div>Harper lives with CTNNB1 Syndrome, an ultra-rare genetic condition caused by changes (mutations) in the CTNNB1 gene. This gene plays a critical role in brain development, muscle tone, vision, communication, and overall neurological function. When it doesn’t work properly, children can face:
</div>
<div><br />
</div>
<div>Significant developmental delays
</div>
<div>Limited or absent speech
</div>
<div>Low or spastic muscle tone
</div>
<div>Balance and coordination challenges
</div>
<div>Vision impairments
</div>
<div>Cognitive disabilities
</div>
<div><br />
</div>
<div>There is currently no cure for CTNNB1 Syndrome. Treatment has only meant supportive therapies — physical therapy, speech therapy, occupational therapy — all focused on helping children reach their fullest potential while managing lifelong challenges.
</div>
<div><br />
</div>
<div>But now, something extraordinary is happening.
</div>
<div><br />
</div>
<div>Harper has been selected as the THIRD child in the world to participate in a groundbreaking human clinical trial for a new gene replacement therapy designed specifically for CTNNB1 Syndrome. This innovative therapy aims to deliver a functional copy of the gene directly to the body, targeting the root cause of the condition rather than just managing symptoms.
</div>
<div><br />
</div>
<div>For families affected by rare genetic disorders, this is more than a trial — it’s hope.
</div>
<div><br />
</div>
<div>If successful, this therapy could:
</div>
<div><br />
</div>
<div>Improve mobility and muscle strength
</div>
<div>Support cognitive development
</div>
<div>Enhance communication abilities
</div>
<div>Slow or halt neurological progression
</div>
<div>Change the standard of care for CTNNB1 Syndrome
</div>
<div><br />
</div>
<div>Beyond Harper, positive trial results could open doors for the entire rare disease community. Gene replacement therapies are paving the way for treating conditions once thought untreatable. Harper’s participation contributes vital clinical data that could help accelerate research, funding, and treatment access for thousands of children living with rare genetic disorders.
</div>
<div><br />
</div>
<div>Being chosen is an incredible honor — but it comes with a significant financial burden.
</div>
<div><br />
</div>
<div>Over the next three years, Harper will undergo:
</div>
<div><br />
</div>
<div>Specialized hospital stays
</div>
<div>Ongoing clinical monitoring
</div>
<div>Extensive follow-up assessments
</div>
<div>Rehabilitation and therapy
</div>
<div>Travel to and from the trial site
</div>
<div>Insurance-related costs not covered by provincial health care
</div>
<div><br />
</div>
<div>The total estimated cost is $250,000 to ensure Harper can complete the full three-year clinical trial and data collection process.
</div>
<div><br />
</div>
<div>Every donation helps cover:
</div>
<div>Travel expenses
</div>
<div>Hospital and medical costs
</div>
<div>Rehabilitation and therapy
</div>
<div>Required follow-up assessments
</div>
<div>Ongoing monitoring until trial completion (2029)
</div>
<div><br />
</div>
<div>This is more than funding medical care.
</div>
<div>This is investing in the future of rare disease treatment.
</div>
<div>This is helping one brave little girl change the world.
</div>
<div><br />
</div>
<div>Harper is funny, determined, and full of light. She works hard every single day to do things many of us take for granted. Now she has the chance to be part of something revolutionary.
</div>
<div><br />
</div>
<div>Please consider supporting Harper’s journey. Share her story. Be part of this historic moment.
</div>
<div><br />
</div>
<div>Together, we can help Harper — and children like her — move closer to a future filled with possibility.
</div>

Alana Hatfield

Anonymous

Mary-Ann Arnold

Sabrina Leboeuf

Bruce Heaton

Lydia Bowie Bowie

This contribution is thanks to Dragonfly earrings purchases Organized by Terra Crowe

Carol Banks

KAYE NASON

Rebecca Stone

Terra Sawlor

Robert J Summerby

Julie MacArthur

Help Harper Make History: Gene Therapy for CTNNB1 Syndrome

platform

Platform is iOS

Android

Adyen Google Pay Development Audience

$opt_dummy_attribute

English only

Deprecate Stripe Legacy

dyn_template_ids

Adyen V6 Bene Transfer & MyMoney Campaign Organizers - test01

Bene transfer V6 and AdyenV6MyMoney Campaign Organizers - production

OneTrust next-app audience

fundCountryCode

NextDoor Share Option Users

Fundraisers with Reactions feature capability

fundCurrencyCode

US + Non-charity COs Only

locale

fund country is US and user language is English

personId

comms-internal-person-ids

Enhanced Story Experience Users

Suggested Goal Experience Users

user language is English and fund country: US, AU, DK, FI, IE, NO, SE, CA, GB; 

Poster share - new funds eligible (newest 9/18)

Streaming widgets beta user

paymentProcessor

3DS payment method

user language is English and fundCountry: US, AU, DK, FI, IE, NO, SE, CA, GB; 

GoFundMe Employees

ipAddress

Mark Rieth IP Address

Version 9.2.0 and above

Fund is in English speaking country

desktop

Android v12.11.0 and above

Platform is Android

paymentMethodType

checkoutType

Payment method type group to be vaulted on success

admin pr kit prod

EUR Donation Upsell

Share Text generation Skip Fundraiser

(prod) new funds eligible for amp12 (UGC gallery)

fintrac_cad_idv_form_v2 audience

paymentProcessorAccountId

fallback mode accounts

proCampaignId

p2p legacy startfundraising page

AMP24 New Funds Only PROD (DO NOT MODIFY)

countryCode

charityId

UKCharities

Federated Search Internal Testing

route.pathname community

US Donation Upsell audience 

Auto Thanks Feature Audience

Supporter Comments Eligible Funds

International Only

fundId

braze fundraiser group 

Payment Identity Transfers ATO Risk Check (Targeted) - Production

Fundraiser Saved Payment Method Rate Limit Bypass (Production)

leaderboard-partner-id-audience-givepanel

Version 9.2.1 and above

AUD Donation Upsell audience

fundraiserCountryCode is US/EN

Active Fundraiser - Smart Default Cadence

DAF Internal

Vault on success card payment method

Platform is iOS v11.0.0 and above

Desktop users

Person ids

United States (US) users

allow yuno fundraisers for test

Mexico country code

Posters INTL

NPO Profile Opted-In

iOS at or above 12.4.0

non-US recurring donors

Canada Campaign Owner Group

Fundraiser Without Meta Link

Scheduler payment tester gorup

charityCommunityId

Charities allow to be claimed unclaimed (PRD)

Canada (CA) users

currencyCode

UC Tipping v20250115 International

pymk_production_xplr_fe_team

Android at or above 12.2.0

Profile photo entry point audience

smart goals (fundraiser/manage) on test01

Activity Tracking v1 Beta Testing

writePath

Stream Notification

start gfm intl allowed locales

Platform is iOS v11.2.0 and above

unclaimed charities

prod_ach_audience

AI Chatbot Audience

amp13 only new funds (prod) (anyword auto)

UC Flow Enabled (Prod)

Payment Identity Beneficiary Verification - Production

shared notification bell audience

Custom users

ach frontend audience

Android v11.0.0 and above

Users Receiving Payments Paused Notifications

smart goals test01

Manage Coach - US English Organizers Only + new funds only

Team EGG - IP Address list

Fundraiser Without Instagram Deep Link

Native 11.4.0 and above

UC Tipping v20250107

Users Receiving Braze KYC Validation Failed

Native 11.3.0 and above

Influencer - Prod

US fundraisers and US users

ai_title_page

anyword

openai

control

manual_entry

userEmail

template_id

userId

fundUrl

isCharityCo

email

appVersion

shouldBucketIntoExperiment

partnerId

donationCadence

isActiveFundraiser

isPartner

isMobile

npoProfileOptIn

fundIsLinkedWithMeta

hasSessionDonation

isCampaignOwner

fundHasInstagramDeepLink

Native 11.4.0 and higher

New funds eligible - Video Sharing (PROD)

GB Donation Upsell audience 

Auto Thanks V3 Rollout Audience

Thank you V3 testing whitelist

isRecurringFriendly

Is Recurring Friendly

Excluded funds - Video Sharing

Logged In Users

CH Donation Upsell audience

Android v10.6.0 and above

userCurrencyCode

Localized Currency

v11.5.0 and above

testAudience

pathname

Survicate

appVersion is at or above 12.8.0

Non-charity fund

isChallengeFundraiser

challenge-fundraisers

Payment Identity Launch Verification - Production

New funds eligible - Posters v2

CAD Donation Upsell Audience

Braze Email Tester

NPO Profile Opted-Out

iOS App Version

hasKnownDonors

PYMK has donors

iOS v12.3.0 and above

Help Harper Make History: Gene Therapy for CTNNB1 Syndrome

Still $146,288 to go. Help us build momentum.